BACKGROUND: Hereditary angioedema (HAE) is a life-threatening, autosomal dominant disorder characterized by unpredictable, episodic swelling of the face, upper airway, oropharynx, extremities, genitalia, and gastrointestinal tract. Almost all cases of HAE are caused by mutations in the SERPING1 gene resulting in a deficiency in functional plasma C1 esterase inhibitor (C1EI), a serine protease inhibitor that normally inhibits proteases in the contact, complement, and fibrinolytic systems. Current treatment of HAE includes long-term prophylaxis with attenuated androgens or human plasma-derived C1EI and management of acute attacks with human plasma-derived or recombinant C1EI, bradykinin, and kallikrein inhibitors, each of which requires repeated administration. As an approach to effectively treat HAE with a single treatment, we hypothesized that a one-time intravenous administration of an adeno-associated virus (AAV) gene transfer vector expressing the genetic sequence of the normal human C1 esterase inhibitor (AAVrh.10hC1EI) would provide sustained circulating C1EI levels sufficient to prevent angioedema episodes. METHODS: To study the efficacy of AAVrh.10hC1EI, we used CRISPR/Cas9 technology to create a heterozygote C1EI-deficient mouse model (S63±) that shares characteristics associated with HAE in humans including decreased plasma C1EI and C4 levels. Phenotypically, these mice have increased vascular permeability of skin and internal organs. RESULTS: Systemic administration of AAVrh.10hC1EI to the S63± mice resulted in sustained human C1EI activity levels above the predicted therapeutic levels and correction of the vascular leak in skin and internal organs. CONCLUSION: A single treatment with AAVrh.10hC1EI has the potential to provide long-term protection from angioedema attacks in affected individuals.
BACKGROUND:Hereditary angioedema (HAE) is a life-threatening, autosomal dominant disorder characterized by unpredictable, episodic swelling of the face, upper airway, oropharynx, extremities, genitalia, and gastrointestinal tract. Almost all cases of HAE are caused by mutations in the SERPING1 gene resulting in a deficiency in functional plasma C1 esterase inhibitor (C1EI), a serine protease inhibitor that normally inhibits proteases in the contact, complement, and fibrinolytic systems. Current treatment of HAE includes long-term prophylaxis with attenuated androgens or human plasma-derived C1EI and management of acute attacks with human plasma-derived or recombinant C1EI, bradykinin, and kallikrein inhibitors, each of which requires repeated administration. As an approach to effectively treat HAE with a single treatment, we hypothesized that a one-time intravenous administration of an adeno-associated virus (AAV) gene transfer vector expressing the genetic sequence of the normal humanC1 esterase inhibitor (AAVrh.10hC1EI) would provide sustained circulating C1EI levels sufficient to prevent angioedema episodes. METHODS: To study the efficacy of AAVrh.10hC1EI, we used CRISPR/Cas9 technology to create a heterozygote C1EI-deficient mouse model (S63±) that shares characteristics associated with HAE in humans including decreased plasma C1EI and C4 levels. Phenotypically, these mice have increased vascular permeability of skin and internal organs. RESULTS: Systemic administration of AAVrh.10hC1EI to the S63± mice resulted in sustained humanC1EI activity levels above the predicted therapeutic levels and correction of the vascular leak in skin and internal organs. CONCLUSION: A single treatment with AAVrh.10hC1EI has the potential to provide long-term protection from angioedema attacks in affected individuals.
Authors: Bruce L Zuraw; Aleena Banerji; Jonathan A Bernstein; Paula J Busse; Sandra C Christiansen; Mark Davis-Lorton; Michael M Frank; Henry H Li; William R Lumry; Marc Riedl Journal: J Allergy Clin Immunol Pract Date: 2013-08-30
Authors: Katsuya Inagaki; Sally Fuess; Theresa A Storm; Gregory A Gibson; Charles F Mctiernan; Mark A Kay; Hiroyuki Nakai Journal: Mol Ther Date: 2006-05-19 Impact factor: 11.454
Authors: Bishnu P De; Adriana Heguy; Neil R Hackett; Barbara Ferris; Philip L Leopold; John Lee; Lorraine Pierre; Guangping Gao; James M Wilson; Ronald G Crystal Journal: Mol Ther Date: 2005-11-02 Impact factor: 11.454
Authors: Amit C Nathwani; Cecilia Rosales; Jenny McIntosh; Ghasem Rastegarlari; Devhrut Nathwani; Deepak Raj; Sushmita Nawathe; Simon N Waddington; Roderick Bronson; Scott Jackson; Robert E Donahue; Katherine A High; Federico Mingozzi; Catherine Y C Ng; Junfang Zhou; Yunyu Spence; M Beth McCarville; Marc Valentine; James Allay; John Coleman; Susan Sleep; John T Gray; Arthur W Nienhuis; Andrew M Davidoff Journal: Mol Ther Date: 2011-01-18 Impact factor: 11.454
Authors: Timothy Craig; Emel Aygören-Pürsün; Konrad Bork; Tom Bowen; Henrik Boysen; Henriette Farkas; Anete Grumach; Constance H Katelaris; Richard Lockey; Hilary Longhurst; William Lumry; Markus Magerl; Immaculada Martinez-Saguer; Bruce Ritchie; Alexander Nast; Ruby Pawankar; Bruce Zuraw; Marcus Maurer Journal: World Allergy Organ J Date: 2012-12 Impact factor: 4.084
Authors: Jonathan B Rosenberg; Alvin Chen; Bishnu P De; Jonathan P Dyke; Douglas J Ballon; Sebastien Monette; Rodolfo J Ricart Arbona; Stephen M Kaminsky; Ronald G Crystal; Dolan Sondhi Journal: Hum Gene Ther Date: 2021-03-30 Impact factor: 4.793
Authors: Nicholas Brodszki; Ashley Frazer-Abel; Anete S Grumach; Michael Kirschfink; Jiri Litzman; Elena Perez; Mikko R J Seppänen; Kathleen E Sullivan; Stephen Jolles Journal: J Clin Immunol Date: 2020-02-17 Impact factor: 8.317